

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of the groups n = 5

EQA round: AP2/21 - Antithrombotic Agents

Deadline: 17.09.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(108) Apixaban					30							30	26	87%
Samples and groups		[µg/L]												
Sample A1		266	26	9,6	30	CVP	266	11	25%	199	333	30	29	97%
(38) IL		287	5,0	1,8	9	0						9		
(63) Sysmex		250	25	10	11	0						11		
(94) Stago		271	17	6,3	7	0						7		
Other					3	0						3		
							1x 149, 1x 162, 1x 179							
Sample B1		65,5	6,4	9,8	30	CVP	65,5	2,9	25%	49,1	81,9	30	26	87%
(38) IL		69,7	0,96	1,4	9	0						9		
(63) Sysmex		58,6	8,1	14	11	0						11		
(94) Stago		66,5	6,7	10	7	0						7		
Other					3	0						3		
							1x 149, 1x 162, 1x 179							
Set 2														
(109) Dabigatran					33							33	30	91%
Samples and groups		[µg/L]												
Sample A2		206	24	12	33	CVP	206	10	25%	154	258	33	32	97%
(38) IL		199	25	13	11	0						11		
(63) Sysmex		203	18	8,8	13	0						13		
(94) Stago		232	11	4,9	6	0						6		
Other					3	0						3		
							1x 149, 1x 162, 1x 179							
Sample B2		50,3	5,1	10	33	CVP	50,3	2,2	25%	37,7	62,9	33	30	91%
(38) IL		50,3	3,2	6,3	11	0						11		
(63) Sysmex		49,8	5,6	11	13	0						13		
(94) Stago		54,7	11	21	6	0						6		
Other					3	0						3		
							1x 149, 1x 162, 1x 179							
Set 3														
(110) Rivaroxaban					37							37	34	92%
Samples and groups		[µg/L]												
Sample A3		313	27	8,7	37	CVP	313	11	25%	234	392	37	36	97%
(38) IL		281	11	4,0	11	0						11		
(63) Sysmex		332	10	3,1	14	0						14		
(94) Stago		318	16	4,9	7	0						7		
Other					5	1						5		
							3x 149, 1x 162, 1x 179							
Sample B3		73,1	5,3	7,3	37	CVP	73,1	2,2	25%	54,8	91,4	37	34	92%
(38) IL		72,7	3,8	5,2	11	0						11		
(63) Sysmex		72,2	5,6	7,8	14	0						14		
(94) Stago		77,9	13	17	7	0						7		
Other					5	1						5		
							3x 149, 1x 162, 1x 179							

st_kn_p

End of report

Printed: 30.09.2021